Innovative Technologies and Services

HWI group is a family-owned, independent service partner in the pharma and biotech sector.

Our end-to-end service concept covers the entire value chain of medicinal products with small and large molecules.

Our portfolio ranges from drug product development, analytical development and quality control, manufacturing of clinical trial batches and small market batches to non-clinical development, pharmacovigilance and GxP services.

HWI looks back on 35 years of experience and a large number of successfully completed projects and drug approvals on behalf of its clients.

HWI's technology platform for parenteral, nasal and oral applications focuses on the development of innovative and affordable drugs with a special focus on challenging small and large active ingredients.

Our purpose is to discover new ways to improve and extend people's lives. With novel technologies and innovative services, HWI aims to advance the development of highly effective medicines for everyone.

Contact

We are happy to discuss your enquiries in person and look forward to hearing from you! Or you can send an email to **sales@hwi-group.de**.

Lilia Selinger
Head of Sales
Mobile: +49 172 2113128
Email: sales@hwi-group.de

Please visit our website www.hwi-group.de for detailed information on our services.

Sign up for our newsletter:
www.hwi-group.de/en/newsletter

Follow us:

Ruelzheim headquarters
HWI pharma services GmbH
Rheinzaberner Strasse 8 | 76761 Ruelzheim | Germany
Phone: +49 7272 7767-0 | info@hwi-group.de
www.hwi-group.de

HWI group



End-to-end Service Concept

Innovative Technologies and Services
for Pharma & Biotech

www.hwi-group.de

HWI group

End-to-end Service Concept

Our services cover the entire value chain of medicinal products with small and large molecules.



Drug development and manufacturing

› Solid, semi-solid and liquid formulations
› Parenteral, nasal, oral and topical applications
› Manufacture of CTM and small commercial batches
› Secondary packaging, labelling, serialisation and aggregation
› Handling of high potent drugs
› High-throughput screening for poorly soluble APIs
› Micro- and nanosuspensions
› Manufacture of commercial sterile products up to 20,000 units – liquid and lyophilised powders (from 2029)

Pharmacovigilance services

› Clinical trial pharmacovigilance and post-marketing pharmacovigilance
› Automated literature search and assessment
› AI supported vigilance processes
› EU-QPPV, Graduated Plan Officer, Information Officer

Analytical development and laboratory services

› Method development and validation
› Purity testing, trace analysis and structure elucidation
› Release testing and ICH stability studies
› Stress testing and forced degradation studies
› Extractables and leachables studies
› Root cause analysis of manufacturing and production issues (troubleshooting)
› Latest test methods in testing drug formulations, APIs, excipients, biologics

QP services and regulatory consulting

› QP batch release
› GxP services and audits
› Application for manufacturing, import and wholesale authorisation
› Implementation and maintenance of quality assurance systems
› Regulatory services

HWI Sites in Germany



Frankfurt Site
› Drug development
› Semi-solid and liquid formulations (incl. parenteral, intranasal)
› Small batches and clinical trial manufacturing

Headquarters, Ruelzheim Site
› Laboratory services
› Pharmacovigilance services
› QP services & regulatory consulting

Appenweier Site
› Drug development
› Solid formulations
› Small batches and clinical trial manufacturing

› Innovative technologies and services for pharma & biotech for small and large molecules
› 2,000 m² lab space
› 600 m² clean rooms
› EU-GMP certified, FDA approved, manufacturing authorisations